 
Stromedix secures broad patent coverage for lead program
MORE (PDF) >
MORE NEWS >
Follow Stromedix on Twitter
GO >
|
|
Stromedix, Inc.
One Canal Park, Suite 1120
Cambridge MA 02141
tel 617.674.8400
fax 617.674.8390
info@stromedix.com |
|
 
STX-100 is Stromedix’s first clinical candidate
and is being developed for the treatment of interstitial fibrosis and
tubular atrophy in kidney transplant recipients.
 |
Humanized monoclonal antibody to integrin αvβ6 |
|
Completed phase 1 clinical testing in 2008 |
|
Provides localized, injury-specific inhibition of TGF-β activation
|
|
Significant anti-fibrotic activity in preclinical models of lung, kidney and liver disease |
|
Broad therapeutic utility in chronic organ failure, acute organ failure and cancer | |
